54562-14-0

Usage

Uses

Used in Pharmaceutical Industry:
GAMMA-LINOLENOYL CHLORIDE is used as an intermediate in the synthesis of γ-Linolenic Acid Ethyl Ester-d5 (L467682) for its application in biological studies. This is because γ-Linolenic Acid Ethyl Ester-d5 is employed in the inhibition of neoplasm in cultured carcinoma cells of human breast, contributing to the development of potential cancer treatments.
Used in Biomedical Research:
GAMMA-LINOLENOYL CHLORIDE is used as a precursor in the production of γ-Linolenic Acid Ethyl Ester, which is utilized in the evaluation of hypocholesterolemic activity in rats. This application aids in understanding the potential benefits of γ-Linolenic Acid Ethyl Ester in managing cholesterol levels and its implications for cardiovascular health.

InChI:InChI=1/C18H29ClO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13H,2-5,8,11,14-17H2,1H3/b7-6-,10-9-,13-12-

Upstream product

• 506-26-3 all-cis-6,9,12-octadecatrienoic acid 

Downstream Products

• 847019-80-1 1,3-di(octadeca-6Z, 9Z, 12Z-enoyloxy)propan-2-one 
• 628-13-7 pyridine hydrochloride 
• 14465-68-0 tri-γ-linolenin 
• 847019-77-6 BGC-20-0134 
• 109791-32-4 ASCORBYL GAMOLENATE 
• 183863-63-0 2,2,2-Trichloroethyl 2-[(z,z,z) octadeca-6,9,12-trienoyloxy] benzoate 
• 150314-37-7 linolenyl ethanolamide 

Relevant academic research and scientific papers

Unsaturation and Polar Head Effect on Gelation, Bioactive Release, and Cr/Cu Removal Ability of Glycolipids

Designing of multifunctional soft and smart materials from natural sources is a useful strategy for producing safer chemicals having potential applications in biomedical research and pharmaceutical industries. Herein, eight glycolipids with variation in unsaturation of hydrophobic tail and polar headgroup size were designed. The effect of unsaturation in the tail group and headgroup size on gelation ability, and mechanical and thermal stability of glycolipid hydro/organogels was studied to understand structure and property relationship. Glycolipids are functional amphiphilic molecules having potential applications in the field of drug delivery and metal removal. The encapsulation capacity and kinetic release behavior of hydrophobic/hydrophilic bioactives like curcumin/riboflavin from the hydrophobic/hydrophilic pockets of glycolipids hydro/organogels was examined. A significant observation was that the glucamine moiety of the glycolipid headgroup plays a vital role in removal of Cr and Cu from oil/water biphasic systems. Typical functions of the glycolipid hydrogels are metal chelation and enzyme-triggered release behavior, enabled them as promising material for Cr, Cu removal from edible oils and controlled release of water soluble/insoluble bioactives.

Amides of N-Deacetyllappaconitine and Unsaturated Fatty Acids

Amides were prepared from N-deacetyllappaconitine and unsaturated oleic, linoleic, α-linolenic, and γ-linolenic fatty acids.

Transdermal Penetration Enhancer and Their Uses

The present invention relates to a transdermal penetrating enhancer comprising an amino sugar-fatty acid conjugate. The conjugate included in the transdermal penetrating enhancer of the present invention can be industrially used in a cosmetic industry pursuing skin health and aesthetic enhancement of skin, and as well as used as a key material for a formulation of a transdermal drug delivery system. The transdermal penetrating enhancer of the present invention has effect of increasing permeability of a bioactive material or a drug into skin. Also, in some cases, the transdermal penetrating enhancer of the present invention can be applied as a single preparation for the therapeutic purpose by preparing a conjugate including a certain drug. Moreover, since the transdermal penetrating enhancer of the present invention uses a conjugate including a material in which skin safety is ensured, the transdermal penetrating enhancer can be applied to various fields besides a cosmetic or medicinal field.

Nonionic diethanolamide amphiphiles with unsaturated C18 hydrocarbon chains: Thermotropic and lyotropic liquid crystalline phase behavior

The neat and lyotropic liquid crystalline phase behavior of three nonionic diethanolamide amphiphiles with C18 hydrocarbon chains containing one, two or three unsaturated bonds has been examined. This has allowed the effect of degree of unsaturation on the phase behavior of diethanolamide amphiphiles to be investigated. Neat linoleoyl and linolenoyl diethanolamide undergo a transition from a glassy liquid crystal to a liquid crystal at ～-85 °C, while neat oleoyl diethanolamide undergoes a transition at ～-60 °C to a liquid crystalline material before re-crystallizing at -34 °C. Oleoyl diethanolamide then undergoes a third transition from a crystalline phase to a smectic liquid crystalline phase at ～5 °C. In the absence of water, the transition temperature from a smectic liquid crystal to an isotropic liquid decreases with increasing unsaturation. The addition of water results in the formation of a lamellar phase (Lα) for all three amphiphiles. The lamellar phase is stable under excess water conditions up to temperatures of at least 70 °C. Approximate partial binary amphiphile-water phase diagrams generated for the three unsaturated C18 amphiphiles indicate that the excess water point for each amphiphile occurs at ～60% (w/w) amphiphile. the Owner Societies 2011.

Chemical compounds

This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula I” herein. Compounds of formula I can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.

CYTOKINE MODULATORS USING CYCLIC GLYCERIDES OF ESSENTIAL POLYUNSATURATED FATTY ACIDS

A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R1 and R2 together form a group -(CH2)n-CR4R5-(CH2)m- wherein n and m are independently selected integers 0, 1 or 2 and R4 and R5 are independently selected from H, C1-18 alkyl, C1-18alkoxy, C1-18n hyroxyalkyl, C2-18 alkenyl and C6-18aryl or aralykyl and R3 is the a fatty acyl group of an essential poyunsaturated fatty acid.

TREATMENT OF CYTOKINE DYSREGULATION BY USING SN-2 GAMMA-LINOLENOYL, GAMMA-DIHOMOLINOLENOYL OR ARACHIDONOYL PATTY ACID GLYCEROL MONOESTERS

A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a monoglyceride or metabolic precursor thereof of general formula (I), wherein R1 is the

TREATMENT OF NEURODEGENERATIVE CONDITIONS

A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels.